Form 4: Harvard Bioscience Director Forfeits Shares Post-Resignation

James W. Green, a Director at Harvard Bioscience Inc., forfeited over 392,000 shares of common stock and RSUs following his resignation from all services with the company.

Summary

• James W. Green, a Director of Harvard Bioscience Inc. (HBIO), reported changes in his beneficial ownership of common stock.
• The transactions occurred on August 15, 2025, and were filed on August 19, 2025.
• Green forfeited a total of 392,522 shares of common stock and restricted stock units (RSUs) due to his resignation from all services with the Issuer.
• This includes 49,048 time-based RSUs granted on March 6, 2023, and 119,332 time-based RSUs granted on March 5, 2024, both forfeited at a price of $0.
• Additionally, 66,036 performance-based RSUs granted on March 6, 2023, and 113,366 performance-based RSUs granted on March 5, 2024, were forfeited at a price of $0.
• He also disposed of 33,200 shares and 11,540 shares, respectively, at a price of $0.529 per share to satisfy tax withholding obligations related to RSU awards that vested on August 15, 2025.
• Following these transactions, Green beneficially owns 2,452,566 shares of common stock directly, which includes 375,005 RSUs with performance-based vesting conditions.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative from an investor's perspective. While the forfeiture of shares by a departing director is a standard event, the departure itself could be seen as a minor negative. However, the filing provides no information to suggest a deeper issue beyond a routine resignation.

Negatives

• Significant reduction in beneficial ownership for the reporting person due to forfeitures.
• The forfeiture of a large number of shares (392,522) indicates a substantial loss of equity compensation for the departing director.
• The resignation of a director can sometimes signal a loss of experience or strategic input for the company.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a standard insider transaction report (Form 4) detailing changes in a director's equity holdings due to resignation. It does not provide broader industry context or trends.

Management Changes

Stakeholder Impact

• Shareholders: The departure of a director may lead to minor concerns regarding board continuity, but the impact is generally limited unless the director held a critical strategic role.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing primarily details the equity transactions of a departing director, which is a routine disclosure for insider changes. It does not contain information that would fundamentally alter the investment thesis for Harvard Bioscience Inc. The resignation of a director, while a change, does not inherently signal a significant positive or negative for the company's operational or financial outlook without further context. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a strong basis for a 'buy' or 'sell' decision.

Keywords

Harvard Bioscience, HBIO, SEC Form 4, Insider Trading, Stock Forfeiture, Restricted Stock Units, Director Resignation, Equity Compensation, Beneficial Ownership